［1］Siegel RL，Miller KD，Jemal A.Cancer statistics，2015 ［J］.Ca A Cancer Journal for Clinicians，2014,64(1):9.
［2］ WANG LJ,LIANG ZX,YU H，et al.Advances in research on driving genes and targeted therapy for lung cancer［J］.Int J Respir，2017,37(4):297-301.［王莉洁，梁志欣，喻航，等.肺癌的驱动基因与靶向治疗研究进展［J］.国际呼吸杂志,2017,37(4):297-301.］
［3］Travis WD，Brambilla E，Nicholson AG，et al.The 2015 world health organization classification of lung tumors ［J］.Seminars in Roentgenology，2015,40(2):90-97.
［4］Zhou X，Cai L，Liu J，et al.Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma［J］.Oncol Lett，2018,16(1):362-370.
［5］Román M，Baraibar I，López I，et al.KRAS oncogene in non-small cell lung cancer:Clinical perspectives on the treatment of an old target［J］.Mol Cancer，2018,17(1):33.
［6］ Rao S，Sigl V，Wimmer RA，et al.RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer［J］.Genes Dev，2017,31(20):2099-2112.
［7］ Ooki A，Dinalankara W，Marchionni L，et al.Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma［J］.Oncogene，2018,37(45):5967-5981.
［8］Tessema M，Yingling CM，Picchi MA，et al.ANK1 methylation regulates expression of microRNA-486-5p and discriminates lung tumors by histology and smoking status［J］.Cancer Lett，2017(410):191-200.
［9］ Yan H，Guan Q，He J，et al.Individualized analysis reveals CpG sites with methylation aberrations in almost all lung adenocarcinoma tissues［J］.J Transl Med，2017,15(1):26.
［10］O'Brien TD，Jia P，Caporaso NE，et al.Weak sharing of genetic association signals in three lung cancer subtypes:Evidence at the SNP，gene，regulation，and pathway levels ［J］.Genome Med，2018,10(1):16.
［11］ Heist RS，Sequist LV，Engelman JA.Genetic changes in squamous cell lung cancer:A review［J］.Journal of Thoracic Oncology,2012,7(5):924-933.
［12］ FU JQ,HA MW.Expression of FGFR1 and VEGF in lung squamous cell carcinoma and its effect on prognosis［J］.Med Phil，2016,37(8):67-70.［付俊青，哈敏文.FGFR1和VEGF在肺鳞癌中的表达及其对预后影响［J］.医学与哲学，2016,37(8):67-70.］
［13］Flockerzi FA，Roggia C，Langer F，et al.FGFR1 gene amplification in squamous cell carcinomas of the lung:A potential favorable prognostic marker for women and for patients with advanced cancer［J］.Virchows Archiv，2018(472):759-769.
［14］Lúcia L Correia，Johnson JA，Mcerlean P，et al.SOX2 drives bronchial dysplasia in a novel organotypic model of early human squamous lung cancer［J］.American Journal of Respiratory and Critical Care Medicine，2017，195(11):1494-1508.
［15］ Boumahdi S，Driessens G，Lapouge G,et al.SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma［J］.Nature，2014，511(7508):246.
［16］ Hussenet T，du Manoir S.SOX2 in squamous cell carcinoma amplifying a pleiotropic oncogene along carcinogenesis［J］.Cell Cycle,2010，9(8):1480-1486.
［17］ Mcgowan M，Hoven AS，Lund-Iversen M，et al.PIK3CA mutations as prognostic factor in squamous cell lung carcinoma［J］.Lung Cancer,2017(103):52.
［18］ Iwakawa R，Kohno T，Totoki Y，et al.Expression and clinical significance of genes frequently mutated in small cell lung cancers defined by whole exome/RNA sequencing［J］.Carcinogenesis,2015,36(6):616.
［19］ Won HH，Pietanza MC，Krug LM，et al.Prospective genomic characterization of small cell lung cancer by targeted next generation sequencing［J］.Cancer Research，2015(75):610.
［20］ George J，Jing SL，Jang SJ，et al.Comprehensive genomic profiles of small cell lung cancer［J］.Nature,2015,524(7563):47-53.
［21］Shue YT，Lim JS，Sage J.Tumor heterogeneity in small cell lung cancer defined and investigated in pre-clinical mouse models［J］.Transl Lung Cancer Res，2018，7(1):21-31.
［22］Byers LA，Wang J，Nilsson MB，et al.Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1［J］.Cancer Discovery,2012,2(9):798.
［23］Kim DW，Kim KC，Kim KB，et al.Transcriptional deregulation underlying the pathogenesis of small，cell lung cancer［J］.Transl Lung Cancer Res，2018,7(1):4-20.
［24］Murai F，Koinuma D，Shinozaki-Ushiku A，et al.EZH2 promotes progression of small cell lung cancer by suppressing the TGF-β-Smad-ASCL1 pathway ［J］.Cell Discov,2015(1):15026.
［25］ Su M，Xiao Y，Tang J，et al.Role of lncRNA and EZH2 interaction/regulatory network in lung cancer［J］.J Cancer,2018,9(22):4156-4165.
［26］ Zhu QG，Zhang SM，Ding XX，et al.Driver genes in non-small cell lung cancer：Characteristics，detection methods，and targeted therapies［J］.Oncotarget，2017,8(34):57680-57692.
［27］ CHEN LF,CHEN XY,YU XB.Relationship between driver gene mutation and clinicopathological features in non-small cell lung cancer［J］.Chin J Pathol，2016,45(4):221-225.［陈灵锋，陈小岩，俞训彬.非小细胞肺癌驱动基因突变与临床病理特征的关系［J］.中华病理学杂志，2016,45(4):221-225.］
［28］ZHANG JJ.Expression and significance of NGAL gene in lung squamous cell carcinoma and lung adenocarcinom［D］.Nanchang:Nanchang University School of Medicine,2015.［张金蛟.NGAL基因在肺鳞癌和肺腺癌组织中的表达及意义［D］.南昌:南昌大学医学院,2015.］
［29］ Lian W，Ouyang Y.CT-guided aspiration lung biopsy for EGFR and ALK gene mutation analysis of lung cancer［J］.Oncology letters，2017，13(5):3415-3422.
［30］Schwaederlé MC，Patel SP，Husain H，et al.Utility of genomic assessment of blood-derived circulating tumor DNA（ctDNA) in patients with advanced lung adenocarcinoma［J］.Clin Cancer Res,2017,23(17):5101-5111.
［31］Alix-PanabieresC，Pantel K.Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy［J］.Cancer Discovery，2016,6(5):479-491.
［32］Normanno N，De LA，Gallo M，et al.The prognostic role of circulating tumor cells in lung cancer［J］.Expert Rev Anticancer Ther，2016，16(8):859-867.
［33］ Rizzo S，Petrella F，Buscarino V,et al.CT radiogenomic characterization of EGFR，K-RAS，and ALK mutations in non-small cell lung cancer［J］.European Radiology，2016,26(1):32-42.
［34］Bak SH，Park H，Lee HY，et al.Imaging genotyping of functional signaling pathways in lung squamous cell carcinoma using a radiomics approach［J］.Scientific Reports，2018，8(1):3284.
［35］ YANG Y,HUANG SM,GANG B，et al.Meta-analysis of the diagnostic value of 18F-FDG PET/CT for EGFR gene mutation in non-small cell lung cancer［J］.Ulrichs IPD,2018，29(5):448-452.［杨洋，黄世明，刚波,等.18F-FDG PET/CT对非小细胞肺癌EGFR基因突变诊断价值的Meta分析［J］.武警医学，2018，29(5):448-452.］
［36］ Van Gool MH，Aukema TS，Hartemink KJ，et al.FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC［J］.World Journal of Radiology，2014，6(7):392-398.
［37］ Wang S，Song Y，Yan F，et al.Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors［J］.Frontiers of Medicine,2016,10(4):383-388.
［38］ Yang JC，Ahn MJ，Kim DW，et al.Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer:AURA study phase Ⅱ extension component［J］.J Clin Oncol,2017,35(12):1288.
［39］Kannan S，Venkatachalam G，Lim HH，et al.Conformational landscape of Epidermal growth factor receptor kinase reveals a mutant specific allosteric pocket［J］.Chemical Science，2018，9(23):5212-5222.
［40］ Jia Y，Yun CH，Park E，et al.Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors［J］.Nature，2016,534(7605):129-132.
［41］ Shaw AT，Ou SH，Bang YJ，et al.Crizotinib in ROS1-rearranged non-small-cell lung cancer［J］.N Engl J Med，2014，371(21):1189-1197.
［42］ Lu S，Zhang J，Ye M，et al.Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer［J］.Pharmacogenomics，2016,17(9):985-994.
［43］ Kato Y，Ninomiya K，Ohashi K，et al.Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions［J］.Cancer Sci,2018,109(10):3149-3158.
［44］Schrank Z，Chhabra G，Lin L，et al.Current molecular-targeted therapies in NSCLC and their mechanism of resistance［J］.Cancers（Basel),2018,10(7):224.
［45］Testa U，Castelli G，Pelosi E.Lung cancers：Molecular characterization，clonal Heterogeneity and evolution，and cancer stem cells［J］.Cancers（Basel),2018,10(8):248.
［46］ Nogova L，Sequist LV，Perez Garcia JM，et al.Evaluation of BGJ398，a fibroblast growth factor receptor 1-3 kinase inhibitor，in patients with advanced solid tumors bearing genetic alterations in fibroblast growth factor receptors：Results of a global phase I，dose-escalation dose-expansion study［J］.J Clin Oncol,2017(35):157-165.
［47］Malchers F，Ercanoglu M，Schütte D，et al.Mechanisms of primary drug resistance in FGFR1 amplified lung cancer［J］.Clinical Cancer Research，2017,23(18):5527-5536.
［48］Yokota E，Yamatsuji T，Takaoka M，et al.Targeted silencing of SOX2 by an artificial transcription factor showed antitumor effect in lung and esophageal squamous cell carcinoma［J］.Oncotarget，2017(61):103063-103076.
［49］ Shi R，Li M，Raghavan V，et al.Targeting the CDK4/6-Rb pathway enhances response to PI3K inhibition in PIK3CA mutant lung squamous cell carcinoma［J］.Clinical Cancer Research，2018,24(23):5990-6000.
［50］ Gadgeel SM.Targeted therapy and immune therapy for small cell lung cancer［J］.Current Treatment Options in Oncology，2018，19(11):53.